Program
Ethinyl Estradiol
Also written as “Gestodene/EE Patch (BAY86-5016)”, “Ethinylestradiol/Gestodene (BAY86-5016)” and “Levonorgestrel/Ethinyl Estradiol”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Metrorrhagia · Premenstrual Syndrome · Hemorrhage · Hot Flashes, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 150 open or running | phase 4since Dec 2, 2005 | Oct 7, 2005 | none ahead |
| Bayer | 130 open or running | phase 4since Sep 12, 2005 | Sep 9, 2005 | none ahead |
| Teva Pharmaceutical Industries | 80 open or running | phase 3since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Pfizer | 70 open or running | phase 3since Aug 8, 2005 | Aug 8, 2005 | none ahead |
| agile-therapeutics | 10 open or running | phase 2since Nov 29, 2010 | Nov 29, 2010 | none ahead |
Also a collaborator on its studies: novum, Eli Lilly and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Aug 8, 2005.
- Sep 4, 2009Phase 3 study in HemorrhageBayer · NCT00984789 · 393 enrolled · Austria, Czech Republic, Netherlands
- Oct 15, 2009Phase 3 study in Pregnancy PreventionTeva Pharmaceutical Industries · NCT00996580 · 3,597 enrolled · United States
- Mar 8, 2010Phase 1 study in ContraceptionBayer · NCT01083264 · 43 enrolled · Germany
- Sep 16, 2010Phase 2 study in ContraceptionBayer · NCT01204190 · 173 enrolled · Germany, Netherlands
- Nov 29, 2010agile-therapeutics's first study: phase 2 study in Ovulation SuppressionNew to agile-therapeuticsagile-therapeutics · NCT01250210 · 123 enrolled · United States
- Feb 4, 2011Phase 1 study in Follicle DevelopmentTeva Pharmaceutical Industries · NCT01291004 · 206 enrolled · United States
- Apr 20, 20112 phase 1 studiesTeva Pharmaceutical Industries · NCT01340625, NCT01344369
- Jul 1, 2011Phase 2 study in ThrombosisTeva Pharmaceutical Industries · NCT01388491 · 293 enrolled · Germany, Israel, Italy and more
- Apr 29, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02127593 · 101 enrolled · Netherlands
- Sep 2, 2015Phase 2 study in ContraceptionBayer · NCT02550977 · 91 enrolled · Russian Federation, Ukraine
- Apr 13, 2017Phase 1 study in HealthyJohnson & Johnson · NCT03126097 · 18 enrolled · United States
- Aug 11, 2017Phase 1 study in HealthyJohnson & Johnson · NCT03249402 · 24 enrolled · Belgium
- May 24, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03547024 · 14 enrolled · Belgium
- Sep 5, 2018Phase 1 study in Healthy FemalesPfizer · NCT03662516 · 17 enrolled · United States
TargetBeta
“Estrogen receptor alpha agonist”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03662516Healthy Females · United States | 1 | Completed | Pfizer | Jan 19, 2019 | 17 |
| NCT03547024Healthy · Belgium | 1 | Completed | Johnson & Johnson | Aug 30, 2018 | 14 |
| NCT03249402Healthy · Belgium | 1 | Completed | Johnson & Johnson | Nov 24, 2017 | 24 |
| NCT03126097Healthy · United States | 1 | Terminated | Johnson & Johnson | May 26, 2017 | 18 |
| NCT02550977Contraception · Russian Federation, Ukraine | 2 | Completed | Bayer | Jul 15, 2016 | 91 |
| NCT02127593Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Sep 2014 | 101 |
| NCT01388491Thrombosis · Germany, Israel, Italy and more | 2 | Completed | Teva Pharmaceutical Industries | Sep 30, 2012 | 293 |
| NCT01344369Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2008 | 36 |
| NCT01340625Bioequivalence · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2007 | 36 |
| NCT01291004Follicle Development · United States | 1 | Completed | Teva Pharmaceutical Industries | Mar 31, 2012 | 206 |
| NCT01250210Ovulation Suppression · United States | 2 | Completed | agile-therapeutics | Feb 2008 | 123 |
| NCT01204190Contraception · Germany, Netherlands | 2 | Completed | Bayer | Jul 2011 | 173 |
| NCT01083264Contraception · Germany | 1 | Completed | Bayer | May 2010 | 43 |
| NCT00996580Pregnancy Prevention · United States | 3 | Completed | Teva Pharmaceutical Industries | Sep 2011 | 3,597 |
| NCT00984789Hemorrhage · Austria, Czech Republic, Netherlands | 3 | Completed | Bayer | Sep 2010 | 393 |
| NCT00933179Contraception · Germany | 2 | Completed | Bayer | Sep 2010 | 30 |
| NCT00924560Bone Mineral Density · United States | 2 | Completed | Teva Pharmaceutical Industries | Aug 2012 | 1,361 |
| NCT00910637Contraception · United States | 3 | Completed | Bayer | Dec 13, 2010 | 1,502 |
| NCT00915915Contraception · Germany | 2 | Completed | Bayer | Apr 2010 | 108 |
| NCT00914693Contraception · Argentina, Australia, Chile and more | 3 | Completed | Bayer | Sep 2011 | 1,694 |
| NCT00873483Contraception · United States | 2 | Completed | Bayer | Mar 3, 2010 | 173 |
| NCT00745901Hemorrhage | 4 | Completed | Johnson & Johnson | Oct 2008 | 355 |
| NCT00729404Contraception · Germany | 2 | Terminated | Bayer | Feb 2009 | 17 |
| NCT00709982Drug Interactions | 1 | Completed | Johnson & Johnson | 47 | |
| NCT00709332Drug Interactions | 1 | Completed | Johnson & Johnson | 47 | |
| NCT00653016Female Contraception | 4 | Completed | Johnson & Johnson | 405 | |
| NCT00447863Contraception | 1 | Withdrawn | Pfizer | 0 | |
| NCT00394771Metrorrhagia · United States | 2 | Completed | Teva Pharmaceutical Industries | Mar 2008 | 567 |
| NCT00344383Metrorrhagia | 2 | Completed | Johnson & Johnson | 61 | |
| NCT00320580Metrorrhagia | 2 | Completed | Johnson & Johnson | 239 | |
| NCT00320567Osteoporosis | 2 | Completed | Johnson & Johnson | 123 | |
| NCT00319163Healthy · United States | 1 | Completed | Pfizer | Nov 2006 | 26 |
| NCT00310531Bone Diseases, Metabolic | 3 | Completed | Bayer | 500 | |
| NCT00307632Contraception · Brazil, Mexico | 4 | Completed | Johnson & Johnson | Dec 2004 | 580 |
| NCT00261482Contraception | 4 | Completed | Johnson & Johnson | 778 | |
| NCT00254189Ovulation | 2 | Completed | Pfizer | 60 | |
| NCT00236782Contraception | 3 | Completed | Johnson & Johnson | 1,517 | |
| NCT00236769Contraception | 3 | Completed | Johnson & Johnson | 1,751 | |
| NCT00195559Premenstrual Syndrome · Argentina, Brazil, Chile and more | 3 | Completed | Pfizer | 526 | |
| NCT00206622Hot Flashes · United States | 4 | Completed | Bayer | 425 | |
| NCT00196326Contraception · United States | 3 | Completed | Teva Pharmaceutical Industries | Jun 2007 | 2,235 |
| NCT00185237Hot Flashes | 3 | Completed | Bayer | Nov 2006 | 165 |
| NCT00161681Premenstrual Syndrome · United States | 3 | Completed | Pfizer | Aug 2006 | 200 |
| NCT00128934Menstruation Disturbances · United States, Canada | 3 | Completed | Pfizer | 744 |
How it is read
Names in the registry
- “Gestodene/EE Patch (BAY86-5016)”, 9 entries
- “Ethinylestradiol/Gestodene (BAY86-5016)”, 6 entries
- “Levonorgestrel/Ethinyl Estradiol”, 5 entries
- “Ethinylestradiol”, 4 entries
- “ethinyl estradiol and levonorgestrel; exenatide”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
- Metrorrhagia, 3 studies
- Premenstrual Syndrome, 3 studies
- Hemorrhage, 2 studies
- Hot Flashes, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.